Gladje Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
- Paid Up Capital ₹ 3.50 M
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 M
About Gladje Pharmaceuticals
Gladje Pharmaceuticals Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 February 2016 (Eight years and 11 months 21 days old ). Its registered office is in Jaipur, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 3.50 M.
The company currently has active open charges totaling ₹3.00 M.
Virendra Narwal, Sandeep Sharma, and Rohit Loona serve as directors at the Company.
Company Details
-
Location
Jaipur, Rajasthan, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232RJ2016PTC049393
-
Company No.
049393
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
24 Feb 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Gladje Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Virendra Narwal
|
Director | 24-Feb-2016 | Current |
|
Sandeep Sharma
|
Director | 24-Feb-2016 | Current |
|
Rohit Loona
|
Director | 24-Feb-2016 | Current |
Financial Performance of Gladje Pharmaceuticals.
Gladje Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gladje Pharmaceuticals?
In 2017, Gladje Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Matteo Formulation Private LimitedRohit Loona is a mutual person
Charges (Loans)
₹3.00 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Jun 2023 | Hdfc Bank Limited | ₹3.00 M | Open |
How Many Employees Work at Gladje Pharmaceuticals?
Unlock and access historical data on people associated with Gladje Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gladje Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gladje Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
